We combine GLP-1 agonist therapy with nutritional guidance, lifestyle coaching, and expert support to ensure safe and effective results
Clinical trials, specifically the 2024 SURMOUNT-1 study, demonstrate that Tirzepatide produces superior weight loss outcomes for most patients
Understanding these variables and working closely with your healthcare provider can help optimise treatment outcomes
The study identified approximately 4,700 people who had been prescribed either semaglutide (Ozempic, Rybelsus and Wegovy) or liraglutide (Saxenda and Victoza)focusing on those who took these drugs for weight loss, not diabetes, with a history of obesity and no diabetic diagnosis
Improperly stored BPC-157 can degrade losing bioactivity, changing purity, and producing inconsistent research results